Do you find our website to be helpful?
Yes   No

Exciting news from Sage, our partner in clinical research

On June 16, 2021, an announcement was made regarding an investigational medication that many of you have participated in at some point over the past four years.  Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder.  While it may have been some time since you were here or you forgot which clinical trial you were in, the news is important for everyone with depression and hopefully, sometime down the road, for those with anxiety.

Dr. Sambunaris & Associates and its sister clinic the Institute for Advanced Medical Research will continue to work with Sage Therapeutics in the conduct of clinical trials for Zuranolone and looks forward to the day that this new and innovative compound achieves FDA approval and availability for patients at their local pharmacy.

Read the full release and details here: https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-positive-pivotal-phase-3

 

Author
Angelo Sambunaris, M.D.

You Might Also Enjoy...

Depression, Fibromyalgia, and chronic pain

Pain can be depressing, and depression creates and exacerbates pain. This cycle can be a dangerous one. In fact, people afflicted by chronic pain are three times more likely to develop psychiatric disorders (most often anxiety or mood disorders).